Stock ABBOTINDIA ABBOTT INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abbott India Limited NSE India S.E.

Equities

ABBOTINDIA

INE358A01014

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:40:46 2024-04-29 am EDT 		5-day change 1st Jan Change
26,290 INR +1.52% Intraday chart for Abbott India Limited +0.62% +15.05%
Apr. 12 Abbott India Limited Appoints Murari Ranganathan as Commercial Director CI
Mar. 19 Abbott India's Managing Director Exits MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 155,053 328,419 318,498 376,101 469,324 558,381 - -
Enterprise Value (EV) 1 155,053 306,445 294,408 348,609 449,953 535,721 531,781 526,061
P/E ratio 34.4 x 55.4 x 46.1 x 47.1 x 49.4 x 46.8 x 41.3 x 36.1 x
Yield 0.69% 0.69% 0.8% 0.82% 0.81% 1.12% 1.28% 1.37%
Capitalization / Revenue 4.21 x 8.02 x 7.39 x 7.65 x 8.77 x 9.48 x 8.49 x 7.61 x
EV / Revenue 4.21 x 7.49 x 6.83 x 7.09 x 8.41 x 9.09 x 8.08 x 7.17 x
EV / EBITDA 25.6 x 40.5 x 32 x 32 x 37.3 x 35.7 x 31.2 x 27.1 x
EV / FCF 31.9 x 50.2 x 41.9 x 38.6 x 52.4 x 51.2 x 45.7 x 37.6 x
FCF Yield 3.14% 1.99% 2.39% 2.59% 1.91% 1.95% 2.19% 2.66%
Price to Book 7.72 x 13.5 x 12.2 x 13.3 x 14.7 x 15 x 13 x 11.1 x
Nbr of stocks (in thousands) 21,249 21,249 21,249 21,249 21,249 21,249 - -
Reference price 2 7,297 15,456 14,989 17,699 22,087 26,278 26,278 26,278
Announcement Date 5/27/19 6/8/20 5/18/21 5/17/22 5/19/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 36,786 40,931 43,100 49,193 53,487 58,912 65,791 73,376
EBITDA 1 6,067 7,564 9,215 10,877 12,056 15,019 17,046 19,396
EBIT 1 5,898 6,968 8,633 10,216 11,357 14,633 16,448 18,618
Operating Margin 16.03% 17.02% 20.03% 20.77% 21.23% 24.84% 25% 25.37%
Earnings before Tax (EBT) 1 6,988 8,027 9,260 10,797 12,738 15,752 17,716 20,019
Net income 1 4,503 5,929 6,907 7,987 9,494 11,878 13,448 15,342
Net margin 12.24% 14.49% 16.03% 16.24% 17.75% 20.16% 20.44% 20.91%
EPS 2 211.9 279.0 325.0 375.9 446.8 561.2 636.9 728.2
Free Cash Flow 1 4,868 6,104 7,034 9,036 8,593 10,469 11,625 14,007
FCF margin 13.23% 14.91% 16.32% 18.37% 16.07% 17.77% 17.67% 19.09%
FCF Conversion (EBITDA) 80.24% 80.69% 76.34% 83.07% 71.27% 69.7% 68.2% 72.22%
FCF Conversion (Net income) 108.1% 102.94% 101.84% 113.13% 90.51% 88.13% 86.45% 91.3%
Dividend per Share 2 50.00 107.0 120.0 145.0 180.0 293.2 336.3 360.4
Announcement Date 5/27/19 6/8/20 5/18/21 5/17/22 5/19/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 10,954 10,955 12,178 12,221 12,244 12,550 13,044 13,795 13,265 13,431 14,790 15,042 14,995 14,696
EBITDA 1 2,418 2,055 2,652 2,597 2,691 2,938 2,704 3,433 3,165 2,801 3,550 3,581 3,658 3,640
EBIT - - - - - - - - 2,987 - - - 3,368 3,654
Operating Margin - - - - - - - - 22.52% - - - 22.46% 24.86%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income 1 1,771 1,525 1,958 1,923 1,992 2,114 2,056 2,655 2,468 2,314 2,902 2,854 2,959 2,859
Net margin 16.17% 13.92% 16.07% 15.74% 16.27% 16.85% 15.77% 19.25% 18.61% 17.23% 19.62% 18.97% 19.73% 19.45%
EPS 83.36 - - 90.51 93.74 99.49 96.77 125.0 116.2 - - - 137.4 142.5
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/9/21 5/18/21 8/6/21 11/12/21 2/9/22 5/17/22 8/10/22 11/14/22 2/10/23 5/19/23 8/9/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 21,974 24,090 27,492 19,371 22,660 26,600 32,320
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 4,868 6,104 7,034 9,036 8,593 10,469 11,625 14,007
ROE (net income / shareholders' equity) 24.3% 26.7% 27.4% 29.5% 31.6% 33.7% 32.6% 32.7%
ROA (Net income/ Total Assets) - 19.9% 18.7% 19.8% 21.6% 23.1% 23.2% 23.5%
Assets 1 - 29,828 36,936 40,322 43,898 51,431 57,904 65,235
Book Value Per Share 2 945.0 1,144 1,225 1,327 1,500 1,750 2,025 2,357
Cash Flow per Share 2 - 295.0 342.0 446.0 420.0 433.0 463.0 609.0
Capex 1 123 157 233 441 341 542 564 584
Capex / Sales 0.33% 0.38% 0.54% 0.9% 0.64% 0.92% 0.86% 0.8%
Announcement Date 5/27/19 6/8/20 5/18/21 5/17/22 5/19/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Abbott India Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.85% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.64% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.57% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.51% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.55% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABBOTINDIA Stock
  4. ABBOTINDIA Stock
  5. Financials Abbott India Limited